Symmetry Medical (NYSE:SMA) recently announced that its subsidiary Symmetry Surgical has launched Bookwalter Femoral Elevator for total hip arthroplasty ("THA") using direct anterior approach ("DAA"). Hospitals and surgery centers can now install the product through SMA's OEM solutions team.
In November last year, I recommend SMA in an article at $8 with a medium-term target of $11.46. In the last few weeks the stock has seen a mild correction from $10.75 to just below $9.50 and I believe that the correction offers a decent buying opportunity, particularly in light of its newest innovation in its industry-leading Bookwalter portfolio coupled with its turnaround initiatives. The stock didn't quite recover since the financial crisis of 2008 because of various internal...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|